Medical technology provider Medtronic and Fitbit joined forces to create a mobile app to help patients with diabetes better track their blood glucose levels and sync data from their wearable devices for more effective diabetes care management.
The iPro2 myLog mobile app allows type 2 diabetes patients to see how their exercise and physical activity habits impact their blood glucose levels in one streamlined application.
The app also aims to simplify the sharing of information with the patient's healthcare team by allowing the patient to receive and access the information on their mobile device rather than manually record the information and communicate it to their physician by memory.
"We believe monitoring glucose is a critical element in the management of diabetes and therefore, glucose should be included among other vital signs. As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the United States," said Laura Stoltenberg, vice president and general manager of non-intensive diabetes therapies at Medtronic.
"We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient's physical activity," said Adam Pellegrini, vice president of digital health at Fitbit. "By partnering with Medtronic, we are able to bring the power of Fitbit's automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation."
More articles on supply:
Medline to complete $20M expansion of flush manufacturing facilities
Case Study: How UAB Medical West transformed its supply chain strategy in one year
Trump vows to lower drug prices — pharma, biotech stocks drop